JP2023551666A5 - - Google Patents

Info

Publication number
JP2023551666A5
JP2023551666A5 JP2023531060A JP2023531060A JP2023551666A5 JP 2023551666 A5 JP2023551666 A5 JP 2023551666A5 JP 2023531060 A JP2023531060 A JP 2023531060A JP 2023531060 A JP2023531060 A JP 2023531060A JP 2023551666 A5 JP2023551666 A5 JP 2023551666A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
approximately
binding fragment
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023531060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551666A (ja
JP7873667B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/060123 external-priority patent/WO2022109291A1/en
Publication of JP2023551666A publication Critical patent/JP2023551666A/ja
Publication of JP2023551666A5 publication Critical patent/JP2023551666A5/ja
Application granted granted Critical
Publication of JP7873667B2 publication Critical patent/JP7873667B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023531060A 2020-11-23 2021-11-19 Ａ型インフルエンザウイルスに対する抗体 Active JP7873667B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063117437P 2020-11-23 2020-11-23
US63/117,437 2020-11-23
US202063123419P 2020-12-09 2020-12-09
US63/123,419 2020-12-09
PCT/US2021/060123 WO2022109291A1 (en) 2020-11-23 2021-11-19 Antibodies against influenza a viruses

Publications (3)

Publication Number Publication Date
JP2023551666A JP2023551666A (ja) 2023-12-12
JP2023551666A5 true JP2023551666A5 (enExample) 2024-11-27
JP7873667B2 JP7873667B2 (ja) 2026-06-12

Family

ID=79021185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531060A Active JP7873667B2 (ja) 2020-11-23 2021-11-19 Ａ型インフルエンザウイルスに対する抗体

Country Status (10)

Country Link
US (1) US20240317841A1 (enExample)
EP (1) EP4247844A1 (enExample)
JP (1) JP7873667B2 (enExample)
KR (1) KR20230135569A (enExample)
AU (1) AU2021382620A1 (enExample)
CA (1) CA3197537A1 (enExample)
IL (1) IL302938A (enExample)
MX (1) MX2023005653A (enExample)
TW (1) TWI901812B (enExample)
WO (1) WO2022109291A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230448A1 (en) * 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
WO2024081639A1 (en) * 2022-10-11 2024-04-18 Seawolf Therapeutics, Inc. Novel lipid nanoparticle compositions for the delivery of nucleic acids

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP3051957B2 (ja) 1997-08-28 2000-06-12 榮太郎 清水 融雪機
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2005028515A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
EP2603237A4 (en) * 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
US8900585B2 (en) * 2010-10-20 2014-12-02 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
TW201806968A (zh) * 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9908930B2 (en) * 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
TWI701258B (zh) * 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CA2975655C (en) * 2015-02-05 2023-09-19 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
SG11202006379UA (en) * 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin

Similar Documents

Publication Publication Date Title
US11136379B2 (en) Binding molecules directed against influenza hemagglutinin and uses thereof
US11926657B2 (en) Neutralizing anti-influenza binding molecules and uses thereof
AU2012346669B2 (en) Influenza A virus specific antibodies
EP2793945B1 (en) Antibodies useful in passive influenza immunization
JP2023551668A5 (enExample)
CN111094335B (zh) 广泛中和的抗流感单克隆抗体及其用途
TWI901812B (zh) 針對a型流感病毒的抗體
JP2025522295A5 (enExample)
WO2026021428A1 (en) Anti-neuraminidase antibodies and uses thereof
HK40069730A (en) Neutralizing anti-influenza binding molecules and uses thereof
HK40061503A (en) Neutralizing anti-influenza binding molecules and uses thereof
HK1253092B (en) Neutralizing anti-influenza binding molecules and uses thereof
HK1250725B (en) Neutralizing anti-influenza binding molecules and uses thereof
HK1203410B (en) Antibodies useful in passive influenza immunization